Staff Directory Contact Us

The Nathan S. Kline Institute for Psychiatric Research

A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Length: 
Approximately 4 months
Disorder/Condition: 
Autism
Inclusion Criteria: 

Males and Females, ages 13-17 with ASD and presence of irritability and GI symptoms

Study Title (brief): 
A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population
Study Description (brief): 

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org

Study Location: 
Nathan Kline Institute, Orangeburg, NY